Company Description
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.
Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications.
In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral β-lactam antibiotics.
The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004.
Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2001 |
| IPO Date | Jun 26, 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Steven Shallcross |
Contact Details
Address: 9605 Medical Center Drive, Suite 270 Rockville, Maryland 20850 United States | |
| Phone | 301 417 4364 |
| Website | therivabio.com |
Stock Details
| Ticker Symbol | TOVX |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 894158 |
| CUSIP Number | 87164U508 |
| ISIN Number | US87164U5083 |
| Employer ID | 13-3808303 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven A. Shallcross CPA | Chief Executive Officer, Chief Financial Officer, Treasurer, Corporate Secretary and Director |
| Dr. Vince Wacher Ph.D. | Head of Product and Corporate Development |
| Dr. Ramon Alemany Ph.D. | Senior Vice President of Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 23, 2026 | 8-K | Current Report |
| Mar 16, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 12, 2026 | 10-K | Annual Report |
| Mar 12, 2026 | 8-K | Current Report |
| Mar 4, 2026 | PRE 14A | Other preliminary proxy statements |
| Feb 18, 2026 | 8-K | Current Report |
| Feb 12, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 5, 2026 | DEF 14A | Other definitive proxy statements |
| Dec 29, 2025 | 8-K | Current Report |